Financials & Filings



News

06 Dec

Fierce Biotech

BioCardia's off-the-shelf cell therapy for heart failure to enter first-in-human study
Read More
01 Dec

Empowered Patient Podcast

Optimizing Autologous Cell Therapy to Treat Cardiovascular Disease with Dr. Peter Altman
Read More
29 Oct

UW Health

UW Health Treats First Patient in U.S. with Investigational Cell Therapy for Heart Disease
Read More
29 Oct

Greenbay CBS

Neenah musician, educator pursues dream after being first in the world to undergo ‘Investigational Cell Therapy’
Read More
29 Oct

WBay.com

Neenah man gets new lease on life after trial heart procedure
Read More
04 Mar

Henry Ford Health System

Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms
Read More

press releases

06 Sep
2023 BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
05 Sep
2023 BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
09 Aug
2023 BioCardia Reports Second Quarter 2023 Business Highlights And Financial Results
02 Aug
2023 BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023
24 Jul
2023 BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
05 Jul
2023 BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS